Incannex Healthcare Inc. (IXHL) Stock Price & Analysis
Incannex Healthcare Inc. (IXHL) fell 6.65% to USD 2.95 as of July 25, 2026 at 07:13 UTC, according to Nexqual real-time market data.
IXHL last closed at USD 3.16; the session ranged USD 2.95–3.17 on volume of 97,211 shares. Market capitalization is $35.30M, with a 52-week range of USD 2.49–39.6 (NCM). Source: Nexqual, July 25, 2026 at 07:13 UTC.
Key Statistics (as of July 25, 2026 at 07:13 UTC)
| Price | USD 2.95 |
|---|---|
| Change | ▼ 6.65% (down) |
| Previous Close | USD 3.16 |
| Open | USD 3.14 |
| Day Range | USD 2.95 – 3.17 |
| 52-Week Range | USD 2.49 – 39.6 |
| Volume | 97,211 shares |
| Market Cap | $35.30M |
| Exchange | NCM |
Technical Analysis (IXHL)
Nexqual's technical model rates IXHL "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 07:13 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.85 (neutral) |
| vs SMA50 | Below (USD 3.46) |
| MACD | -0.13 (negative) |
Analyst Ratings (IXHL)
Wall Street analysts rate IXHL "None" based on 1 analysts, with a mean price target of USD 17.78 (range USD 17.78–17.78), per Nexqual as of July 25, 2026 at 07:13 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 17.78 |
| High Target | USD 17.78 |
| Low Target | USD 17.78 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (IXHL)
| EPS Estimate | USD -0.57 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.49 vs est -0.84 ▲ beat |
| 2025-12-31 | USD -0.85 vs est -0.93 ▲ beat |
| 2025-09-30 | USD -0.92 vs est -18.09 ▲ beat |
| 2025-06-30 | USD -23.26 vs est -13.47 ▼ miss |
Source: Nexqual, July 25, 2026 at 07:13 UTC.
Financials & Fundamentals (IXHL)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -117.17% |
| Debt / Equity | 0.15 |
| Current Ratio | 41.57 |
| Total Cash | $74.45M |
| Total Debt | $114,000 |
| Free Cash Flow | $-8.27M |
Source: Nexqual, July 25, 2026 at 07:13 UTC.
Financial Health Score (IXHL)
Nexqual rates Incannex Healthcare Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 07:13 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $74M cash, no debt |
| Cash Flow | Weak — FCF negative: -$8M, burning cash |
| Efficiency | Critical — ROE -117%, ROA -32.2% |
Ownership (IXHL)
| Insider Ownership | +12.34% |
|---|---|
| Institutional Ownership | +12.09% |
| Shares Outstanding | 11.96M |
| Float | 9.87M |
| Short % of Float | +8.50% |
Source: Nexqual, July 25, 2026 at 07:13 UTC.
Leadership (IXHL)
Incannex Healthcare Inc. is led by Joel Bradley Latham (age 36), President, CEO & Executive Director, per Nexqual as of July 25, 2026 at 07:13 UTC.
| President, CEO & Executive Director | Joel Bradley Latham (age 36) |
|---|---|
| CFO, Treasurer & Secretary | Joseph Swan (age 34) |
| CTO & Member of Advisory Board | Lekhram Changoer M.Sc. (age 58) |
| Chief Scientific Officer, Head of Programs & Member of the Advisory Board | Mark Bleackley |
Major Backers & Investors (IXHL)
Notable institutional backers of Incannex Healthcare Inc. include Polar Asset Management Partners Inc., Ghisallo Capital Management, LLC, Mirae Asset Global ETFs Holdings Ltd., according to Nexqual as of July 25, 2026 at 07:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Polar Asset Management Partners Inc. | 5.22% |
| Ghisallo Capital Management, LLC | 1.36% |
| Mirae Asset Global ETFs Holdings Ltd. | 1.25% |
| Murchinson Ltd. | 0.87% |
| Arete Wealth Advisors, LLC | 0.61% |
| LPL Financial LLC | 0.59% |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.51% |
| UBS Group AG | 0.34% |
Source: Nexqual, July 25, 2026 at 07:13 UTC.
From Incannex Healthcare Inc.'s Latest SEC 10-K Filing (filed 2025-09-29)
Key Strengths & Strategy (as disclosed to the SEC)
- Food and Drug Administration (the "FDA") to obtain guidance on planned next steps, including a pivotal Phase 3 trial design.   PSX-001, our drug candidate in Phase 2 clinical development, is an oral synthetic psilocybin treatment, administered in combination with psychological therapy for patients with moderate-to-severe generalized anxiety disorder ("GAD").
- FDA approval is required before any new drug, including any new indication for a previously approved drug, can be marketed in the United States.   The steps required before a drug may be marketed in the United States generally include the following:       14                     Clinical Development   Before any drug candidate may be tested in humans, it must undergo rigorous preclinical testing.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HCTI | Healthcare Triangle, Inc. | USD 1.62 | ▼ 7.95% |
| AIRE | reAlpha Tech Corp. | USD 1.38 | ▲ 8.66% |
| ATCH | AtlasClear Holdings, Inc. | USD 0.18 | ▼ 16.98% |
| NVNI | Nvni Group Limited | USD 1.13 | ▼ 4.24% |
| BURU | Nuburu, Inc. | USD 0.07 | ▲ 73.1% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:13 UTC. This page is informational and not investment advice.